Navigation Links
BioGenex Completes Construction of a State-of-the-Art Center for Cancer Diagnostics and Molecular Pathology Innovation in Hyderabad, India
Date:2/16/2016

FREMONT, Calif., Feb. 16, 2016 /PRNewswire/ -- BioGenex, a global leader and innovator in providing customer-centric molecular pathology solutions, complete walk-away kits and automation for diagnosis, prognosis, and therapy selection for cancer, is pleased to announce the completion of the Phase I Construction of the Center of Excellence in Hyderabad, India. The 100,000-SqFt Center of Excellence is located on a 20-acre site in the Special Economic Zone (SEZ) of Hyderabad, a large business hub located right off the Outer Ring Road- a 158 kilometer expressway allowing speeds up to 120km/hr. This centralized location and proximity to RGI Airport, a short 35-minute drive away, allows for more efficient international business transactions. This new township will have over 40,000 employees by the end of 2016. TCS (Tata Consultancy) and TATA Advance Systems are among other major institutions building large facilities in the area. BioGenex will use this facility for design and development of multiple new molecular pathology systems and for manufacturing of Xmatrx family instruments. As part of our phased transition, BioGenex's instrument manufacturing, supply chain, stock rooms, R&D, engineering, and QA departments have already moved into the facility.

Photo - http://photos.prnewswire.com/prnh/20160215/333139

Though the facility aims to provide support to both domestic and international markets, global exports will be the key focus area. To help meet the demands of the growing business, the new facility houses complete manufacturing capability for BioGenex's suite of molecular pathology work systems along with the supporting reagents and consumables. The facility also allows for expanded training for our international and domestic distributors and customers.

"This is an important move for BioGenex to ensure that we understand our customer's requirements and tailor our products to meet their needs. Our location in Hyderabad establishes a regional presence with global support capabilities to provide timely product delivery, enhance technical support, complete laboratory set-up for training and to facilitate new product development and launch," said Dr. Krishan Kalra, CEO of BioGenex.

At BioGenex we are committed to providing products and instruments for Molecular Pathology clinical and research. This is one of the steps we are taking to fulfill that commitment.

For more information visit www.biogenex.com

New Facility Address
Aerospace & Precision Engineering SEZ
Hyderabad, India 
Click for directions

About BioGenex

BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.

Visit us at www.biogenex.com

Contact Information
Jay Kishan
49026 Milmont Drive; Fremont, CA 94538
Tel: +1-510-824-1442; Email 
Website: www.biogenex.com


'/>"/>
SOURCE BioGenex Laboratories
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. BGI-Shenzhen Completes Acquisition of Complete Genomics
2. Novira Therapeutics Completes $25 Million Series A Financing
3. bioRASI Completes Acquisition of Ukrainian CRO
4. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
5. St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
6. Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs
7. Oligomerix, Inc. Completes Series B Financing
8. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Boston Scientific Completes $1.05 Billion Senior Notes Offering
11. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions ... scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... At its ... Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has ... was a member of the winning team for the 2015 Breakthrough Prize in Fundamental ...
(Date:10/7/2017)... Arizona (PRWEB) , ... October ... ... 15 years’ experience providing advanced instruments and applications consulting for microscopy and ... in-house expertise in application consulting, Nanoscience Analytical offers a broad range of ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):